search for




 

A Patient with Alzheimer’s Dementia Occurring Additional Extrapyramidal Tract Symptoms
Korean J Clin Geri 2017 Dec;18(2):113-117
Published online December 29, 2017;  https://doi.org/10.15656/kjcg.2017.18.2.113
Copyright © 2017 The Korean Academy of Clinical Geriatrics.

Kipyeong Jeon, Seunghee Na

Department of Neurology, College of Medicine, The Catholic University of Korea, Incheon, Korea
Received June 8, 2017; Revised August 8, 2017; Accepted August 18, 2017.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
 Abstract
Overlap between neurodegenerative disorders is not rare. A 72-year-old woman was admitted to our hospital with resting tremor and bradykinesia which had occurred 6 months ago. She was diagnosed with Alzheimer’s dementia 4 years ago. F-18 florbetaben positron emission tomography (PET) revealed diffuse florbetaben uptake and F-18 FP-CIT PET showed decreased striatal dopamine transporter uptake. Herein, we report a patient having both Alzheimer’s dementia and Parkinson’s disease at the same time.
Keywords : Alzheimer’s dementia, Extrapyramidal symptoms, Parkinson’s disease, Molecular imaging
References
  1. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011;7:280-92.
    Pubmed KoreaMed CrossRef
  2. Chui HC, Lyness SA, Sobel E, Schneider LS. Extrapyramidal signs and psychiatric symptoms predict faster cognitive decline in Alzheimer's disease. Arch Neurol 1994;51:676-81.
    Pubmed CrossRef
  3. Haan MN, Jagust WJ, Galasko D, Kaye J. Effect of extrapyramidal signs and Lewy bodies on survival in patients with Alzheimer disease. Arch Neurol 2002;59:588-93.
    Pubmed CrossRef
  4. Jellinger K, Seppi K, Wenning G, Poewe W. Impact of coexistent Alzheimer pathology on the natural history of Parkinson’s disease. J Neural Transm (Vienna) 2002;109:329-39.
    Pubmed CrossRef
  5. Tsolaki M, Kokarida K, Iakovidou V, Stilopoulos E, Meimaris J, Kazis A. Extrapyramidal symptoms and signs in Alzheimer’s disease: Pravalence and correlation with the first symptom. Am J Alzheimers Dis Other Demen 2001;16:268-78.
    Pubmed CrossRef
  6. Molsa PK, Marttila RJ, Rinne UK. Extrapyramidal signs in Alzheimer’s disease. Neurology 1984;34:1114-6.
    Pubmed CrossRef
  7. Horvath J, Burkhard PR, Herrmann FR, Bouras C, Kövari E. Neuropathology of parkinsonism in patients with pure Alzheimer’s disease. J Alzheimers Dis 2014;39:115-20.
    Pubmed
  8. Ceravolo R, Volterrani D, Gambaccini G, Bernardini S, Rossi C, Logi C, et al. Presynaptic nigro-striatal function in a group of Alzheimer’s disease patients with parkinsonism: evidence from a dopamine transporter imaging study. J Neural Transm (Vienna) 2004;111:1065-73.
  9. Tyrrell PJ, Sawle GV, Ibanez V, Bloomfield P, Leenders K, Frackowiak RS, et al. Clinical and positron emission tomographic studies in the ‘extrapyramidal syndrome’ of dementia of the Alzheimer type. Arch Neurol 1990;47:1318-23.
    Pubmed CrossRef
  10. Rinne JO, Sahlberg N, Ruottinen H, Någren K, Lehikoinen P. Striatal uptake of the dopamine reuptake ligand [11C] -CFT is reduced in Alzheimer’s disease assessed by positron emission tomography. Neurology 1998;50:152-6.
    Pubmed CrossRef
  11. Donaghy P, Thomas AJ, O'Brien JT. Amyloid PET imaging in lewy body disorders. Am J Geriatr Psychiatry 2015;23:23-37.
    Pubmed CrossRef
  12. Treglia G, Cason E. Diagnostic performance of myocardial innervation imaging using MIBG scintigraphy in differential diagnosis between dementia with lewy bodies and other dementias:a systematic review and a meta-analysis. J Neuroimaging 2012;22:111-7.
    Pubmed CrossRef
  13. Tateno F, Sakakibara R, Kawai T, Kishi M, Murano T. Alpha-synuclein in the cerebrospinal fluid differentiates synucleinopathies (Parkinson disease, dementia with Lewy bodies, multiple system atrophy) from Alzheimer disease. Alzheimer Dis Assoc Disord 2012;26:213-6.
    Pubmed CrossRef

 

December 2017, 18 (2)